2022
The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders
Asch R, Hillmer A, Baldassarri S, Esterlis I. The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders. International Review Of Neurobiology 2022, 168: 265-310. PMID: 36868631, DOI: 10.1016/bs.irn.2022.10.007.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersGlutamatesHumansMental DisordersMood DisordersReceptor, Metabotropic Glutamate 5ConceptsPsychiatric disordersMetabotropic glutamate receptor 5Positron emission tomography studyGlutamate receptor 5Utility of PETEmission tomography studiesPromising therapeutic targetStress-related disordersNumerous psychiatric disordersTreatment trialsGlutamate neurotransmissionGlutamate systemMGlu5 expressionSubtype 5Treatment responseMood disordersRole of mGlu5Receptor 5Therapeutic targetPsychiatric conditionsMGlu5Tomography studySubstance useTrauma disordersDisorders
2020
Simplified Quantification of 11C-UCB-J PET Evaluated in a Large Human Cohort
Naganawa M, Gallezot JD, Finnema SJ, Matuskey D, Mecca A, Nabulsi NB, Labaree D, Ropchan J, Malison RT, D'Souza DC, Esterlis I, Detyniecki K, van Dyck CH, Huang Y, Carson RE. Simplified Quantification of 11C-UCB-J PET Evaluated in a Large Human Cohort. Journal Of Nuclear Medicine 2020, 62: 418-421. PMID: 32646875, PMCID: PMC8049341, DOI: 10.2967/jnumed.120.243949.Peer-Reviewed Original Research